PacBio and Intus Bio collaborate for launch of GutID, first at-home microbiome test powered by HiFi sequencing

PacBio, developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, have unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.

Offering the highest resolution analysis possible, GutID is a major breakthrough as it delivers robust and repeatable results, which can be used with confidence to help understand and manage the microbiome, a known critical driver of health outcomes including cancer.

“We are proud to partner with PacBio for their first human health-related commercial application,” said Paul Denslow, CEO of Intus Bio. “High accuracy, long-read sequencing is essential to Intus Bio’s ability to unlock the microbiome, making GutID not just a test, but a transformative tool for understanding and improving human health. It’s already having an incredible impact.”

Recommended by healthcare professionals, GutID provides previously unobtainable gut health information. The test lets the user easily collect and ship a sample from home to a state-of-the-art lab, where PacBio’s long-read sequencing and Intus Bio’s Titan-1 platform combine to power comprehensive, actionable reports.

Each report includes a detailed visualization of bacteria down to the strain level, showing the abundance of both commensals and pathogens. Users also receive a proprietary microbiome health score and personalized recommendations to optimize gut and overall wellness.

GutID is already transforming the lives of individuals with IBS, IBD, and those focused on longevity by offering insights which were previously unavailable.

“We are thrilled to see Intus Bio leveraging PacBio’s advanced sequencing solutions to uncover microbial communities far beyond traditional methods,” said David Miller, Vice President of Marketing at PacBio. GutID showcases the transformative power of our long-read sequencing platforms, opening new frontiers in healthcare by providing deeper insights into the human microbiome and improving human health.”

The microbiome – the vast collection of bacteria in every human – is well established as a critical driver of health outcomes. It has been associated with cancer, autoimmune, neurodegenerative, and other chronic diseases as well as behavioral disorders. A complete, accurate and detailed view of the bacterial microbiome is central to actionability, allowing interventions and lifestyle changes to be made and tracked with confidence.

Despite the microbiome’s well understood potential to impact healthcare, previous generations of microbiome tests have been low resolution, resulting in variable results and limited utility for improving and managing health. By combining Intus Bio’s strain-level microbiome platform and the power of PacBio’s sequencing technology, GutID offers both consumers and clinicians repeatable and robust results for actionable insights.

Want more of the latest science news straight to your inbox? Become a member of SelectScience for free today>>